Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.70 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.70 |
| ▸ | HTR3B | O95264 | 1/20 | 0.70 |
| ▸ | BACE1 | P56817 | 1/20 | 0.70 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.70 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MASP2 | O00187 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | FABP6 | P51161 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 4/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216615 | 0.98 | HTR3E (0.72) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL5679783 | 0.84 | BACE1 (0.59) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL658809 | 0.82 | HTR3E (1.00) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| Bromide SCHEMBL2381776 | 0.82 | BACE1 (0.53) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL117352 | 0.80 | BACE1 (0.54) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL14920005 | 0.78 | HTR3E (0.53) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL1192946 | 0.78 | F7 (0.47) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL118057 | 0.78 | MEN1 (0.57) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL29449363 | 0.78 | MEN1 (0.57) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL1171146 | 0.78 | ALDH1A1 (0.53) | HTR3EHTR3BHTR3ABACE1HTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | 4SC AG (DE) | 2018-06-26 | — | — | US | disclosed |
| US-20160137637-A1 | 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS | 4SC DISCOVERY GMBH (DE) | 2016-05-19 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | HTR3A 2825/4885HTR3E 2083/4885HTR3B 1609/4885 |
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | DYRK2, DYRK1B, DYRK1A | HTR3A 3177/4885HTR3E 2121/4885HTR3B 2600/4885 |
| US-20160137637-A1 | 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS | DYRK2, DYRK1B, DYRK1A | HTR3A 3177/4885HTR3E 2121/4885HTR3B 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.